Bladder Tumor-Targeting Peptide for Specific Diagnosis and Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing bladder tumors are either time-consuming and prone to missed detections through cytology or invasive and inconvenient through endoscopy, and existing drug delivery systems face challenges with immune responses and low tissue infiltration efficiency.
Innovation Solution
Development of a bladder tumor-targeting peptide with an amino acid sequence CXNXDXRXC, specifically identified using phage peptide display technique, which can bind selectively to bladder tumor cells for diagnosis and potentially used as an intelligent drug carrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cytology of bladder is used for diagnosis, then tumor cells can be identified with correct diagnosis, but it is time-consuming and has great possibility of failing to notice tumor cells
Solution Approach 1:
The invention extracts and utilizes specific amino acid sequences (peptides) that are naturally present in or associated with bladder tumor cells. By isolating these specific peptide markers and using them for detection, the method achieves rapid and accurate diagnosis without requiring time-consuming conventional cytological examination procedures.
Solution Approach 2:
The invention replaces the manual mechanical process of conventional cytology (staining, microscopic observation by pathologists) with a biochemical detection system based on peptide-antibody or peptide-receptor interactions. This substitution enables automated, rapid, and highly specific detection of bladder tumor cells.
2Measurement precision
If endoscopy of bladder is used for diagnosis, then tumor can be screened directly inside bladder, but it puts subject into inconvenience by inserting endoscope through urethra
Solution Approach 1:
The invention extracts specific peptide markers from bladder tumor cells and uses these extracted markers for diagnosis. This approach eliminates the need for invasive endoscopic procedures, as the peptide-based detection can be performed on urine samples or tissue biopsies, significantly improving patient convenience while maintaining diagnostic accuracy.
Solution Approach 2:
The invention uses specific peptides as intermediary markers that can be detected in urine or tissue samples. These peptide intermediaries provide indirect but highly accurate information about the presence of bladder tumors, replacing the need for direct visual inspection via endoscope and thereby improving patient comfort.
3Reliability
If antibody is used for targeting therapy, then tumor cell targeting is achieved, but it causes immune responses and has low tissue-infiltration efficiency
Solution Approach 1:
The invention uses short peptides (typically 5-20 amino acids) instead of large antibodies as targeting molecules. These short peptides are less immunogenic, have smaller molecular weights that facilitate tissue penetration, and can be synthesized readily. The peptides serve as disposable targeting agents that guide therapeutic drugs to tumor cells without triggering significant immune responses.
Solution Approach 2:
The invention changes the molecular parameters of the targeting agent from large antibodies (molecular weight 150-200 kDa) to small peptides (molecular weight 1-5 kDa). This parameter change reduces immunogenicity, improves tissue infiltration efficiency, and enhances cellular uptake while maintaining tumor-targeting specificity through carefully designed amino acid sequences.
4Reliability
If conventional anti-tumor agent is used, then tumor treatment is provided, but side effects adversely affecting normal tissue occur
Solution Approach 1:
The invention segments the therapeutic system into two distinct components: a targeting component (specific peptide that binds to bladder tumor cells) and a therapeutic component (anti-tumor agent). The peptide segment guides the therapeutic agent specifically to tumor cells, while the therapeutic segment provides the anti-cancer effect. This segmentation ensures that the anti-tumor agent is delivered selectively to tumor tissue, minimizing exposure and damage to normal tissues.
Solution Approach 2:
The invention uses a specific peptide as an intermediary carrier that mediates the delivery of anti-tumor agents to bladder tumor cells. The peptide intermediary binds to receptors or markers on the surface of bladder tumor cells and facilitates the transport of the therapeutic agent specifically to the tumor site, thereby reducing systemic side effects while maintaining anti-tumor efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide enables accurate and convenient diagnosis of bladder tumors with high specificity and reduced side effects by selectively targeting bladder tumor cells, improving diagnostic efficiency and treatment efficacy.
Implementation Method 1
the peptide according to the present invention is capable of specific binding to a bladder tumor cell
Data Source
AI summary
The present invention relates to a bladder tumor-targeting peptide and use thereof. More particularly, the present invention relates to a bladder tumor-targeting peptide having an amino acid sequence represented by SEQ ID NO: 7 and use thereof. The peptide according to the present invention is capable of specific binding to bladder tumor cells in vivo and in vitro. The peptide according to the present invention or an antibody thereof is useful for a marker for the diagnosis of bladder tumors, and for a drug carrier targeting bladder tumor.